Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 19Lymphoma, Mantle-Cell 9Lymphoma, Non-Hodgkin 4Multiple Myeloma 3Lymphoma, Large B-Cell, Diffuse 3Waldenstrom Macroglobulinemia 2Recurrence 2Pancreatic Neoplasms 2Lymphoma, Follicular 2Lymphoma, B-Cell, Marginal Zone 2Lymphoma 2Squamous Cell Carcinoma of Head and Neck 1Pyloric Stenosis, Hypertrophic 1Ovarian Neoplasms 1Neoplasm, Residual 1Lymphoma, B-Cell 1Leukemia, Prolymphocytic 1Leukemia, Hairy Cell 1Leukemia 1Immunoproliferative Disorders 1Immune System Diseases 1Hodgkin Disease 1Glioblastoma 1DLBCL 1Chromosome 17 deletion 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1Burkitt Lymphoma 1Anemia, Hemolytic, Autoimmune 1Advanced Haematological Malignancies 1

Interventions

acalabrutinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Advanced Haematological Malignancies × acalabrutinib × Clear all
NCT04630756 2025-04-09

AZD4573 in Novel Combinations With Anti-cancer Agents in Patients With Advanced Blood Cancer

AstraZeneca

Phase 1/2 Completed
40 enrolled 31 charts

Advanced Haematological Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡